Newly-released Cell and Gene Therapy Manufacturing Market analysis report by Future Market Insights shows that global sales of the Cell and Gene Therapy Manufacturing Market in 2022 were held at US$ 15.6 Billion. With a CAGR of 29% from 2023 to 2033, the market is expected to reach a valuation of US$ 240 Billion. Market revenue through Cell Therapy Manufacturing is expected to be the highest revenue-generating segment, accounting for an expected CAGR of 31.8% from 2023 to 2033.
| Attribute | Details |
|---|---|
| Global Cell and Gene Therapy Market (2023) | US$ 19.3 Billion |
| Global Cell and Gene Therapy Market (2033) | US$ 240 Billion |
| Global Cell and Gene Therapy Market CAGR (2023 to 2033) | 29% |
| USA Cell and Gene Therapy Market CAGR (2023 to 2033) | 28.5% |
| Key Companies Profiled |
|
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
As per the Cell and Gene Therapy Manufacturing Market research by Future Market Insights - a market research and competitive intelligence provider, historically, from 2018 to 2022, the market value increased at around 22% CAGR.
The rising frequency of cancer and other target diseases, as well as increasing research and development spending in pharmaceutical companies, are driving market expansion. GLOBOCAN 2020 has been revised by the International Agency for Research on Cancer (IARC), which reveals that the worldwide cancer burden has increased to 19.3 million cases and 10 million cancer deaths in 2020.
According to a new study, more than 50 million people will be diagnosed with cancer within the next five years. Aging populations and socioeconomic risk factors are two of the most common causes of cancer cases worldwide. Breast cancer is also one of every four cancers diagnosed in women worldwide, according to the same source.
Breast cancer has surpassed lung cancer as the most commonly diagnosed cancer worldwide for the first time, owing to its high incidence in low- and middle-income nations. Because cancer is one of the most complex diseases, cell and gene therapy is one of the fields with a significant opportunity for cancer treatment.
Immunotherapy, gene transfer, and oncolytic virotherapy are three separate gene therapy treatment techniques that can be used to treat cancer. As the number of instances increases, so will the reliance on gene therapy, thus driving the market growth.
There are around 1,200 cell and gene therapies in clinical trials globally. In the USA alone, there are over 700 investigational cell and gene therapies in clinical trials. Manufacturing facilities, on the other hand, have not kept up. Hundreds of more facilities are expected to be required to manufacture the therapies currently in clinical development. Viral capacity is one of the areas that has to be accelerated.
A large proportion of viral vectors are made utilizing adherent manufacturing, which is costly to run-a vial of 20 million cells can cost anywhere between US$ 20,000 and US$ 30,000 to generate. The cost of producing gene therapy can range from US$ 500,000 to US$ 1 million, excluding research and development, clinical trial costs, and the costs of establishing the commercial infrastructure required to offer access to patients.
Principal Consultant
The market in Asia Pacific is expected to offer a significant opportunity to the market owing to the continuous developments taking place in the regional marketplace. Best practices are being discovered in cell and gene therapy manufacturing as well as in scaling out strategies, process development, cost optimization, advancements in CAR-T manufacturing, and preparation for commercialization.
Companies such as BeiGene, Gracell Biotechnologies, Fosun Kite Biotechnology, Tessa Therapeutics, CARSgen, Senlang Bio, Kangstem Biotech, Medigen Biotechnology Corp, and Shangai UniCAR Therapy have been actively engaged in the advancement of concurrent techniques.
The USA accounted for a significant proportion of the cell and gene therapy manufacturing market revenues in 2022. The key driving factors for the market expansion in the country are a large number of active clinical trials, as well as the growing engagement of firms in gene and cell therapy research and development. With more than 400 businesses actively engaged in the development of cell and gene therapy products for various diseases, North America was ranked top for having the most gene therapy clinical trials.
The market in the United Kingdom is expected to reach a valuation of US$ 6.5 Billion by 2033. Growing with a CAGR of 23.9% in the forecast period, the market in the country is projected to garner an absolute dollar opportunity of US$ 5.7 Billion.
In Japan, the market is expected to grow at a CAGR of 32.5% from 2023 to 2033, reaching US$ 12.6 Billion by 2033. The market in the country is expected to gross an absolute dollar opportunity of US$ 11.9 Billion during the forecast period.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Cell therapy manufacturing led the cell and gene therapy manufacturing market, accounting for a significant proportion of revenue. The high number of active clinical trials and the increasing number of goods entering the market are both contributing to the rise.
To understand the potential of cell therapies for the treatment of various cancer indications, more than 250 clinical trials concentrating on CAR T cell treatments and other cell therapies are explored. Furthermore, biopharma companies are seeing allogeneic CAR T cell therapy as a more attractive business strategy than traditional manufacturing and business models.
The robust and continually developing pipeline of cell and gene therapies around the world has fuelled the rise of the pre-commercial/ research and development scale manufacturing industry. More than 1,000 clinical trials for various cell treatments were currently conducted as of March 2020. According to the Journal of Gene Medicine, the number of gene therapy clinical studies increased to 3,025 in 2019. This high figure reflects the rising need for manufacturing services in the development of preclinical product candidates.
The key contribution to this area is the presence of a significant number of huge capital businesses, as well as academic institutes with tailored patient treatment programs. Greater process troubleshooting agility, ownership of supply channels, and the efficient development of a corporate knowledge base to aid future in-house scale-up are the prominent factors driving the segment growth.
The growing popularity of sophisticated medicines has heightened market competitiveness among participants. Contracts and agreements are being signed between cell therapy manufacturing businesses and CDMOs in order to accelerate product development and acquire a competitive advantage.
The contract-manufacturing segment's revenue has also been boosted by ongoing clinical research projects. Furthermore, more than 65% of the cell and gene therapy manufacturing process is outsourced, which is expected to further reduce costs and add to the market growth.
The development of well-characterized and robust technologies for cell therapy production has become increasingly vital owing to an increasing number of medicines progressing from clinical trials to regulatory approval. Process development solutions improve the quality and safety profiles of candidate programs while increasing efficiency.
This segment, on the other hand, is predicted to increase at the fastest rate throughout the forecast period due to the significant penetration of manufacturing services in the vector production area. The viral vectors have been used to treat a variety of disorders, including cardiovascular, metabolic, hematologic, muscular, infectious, and ophthalmologic conditions, as well as numerous types of cancer.
The growing interest of public and private investors in the development of advanced therapies is expected to boost market revenue during the forecast period. In addition, key firms are enhancing their market presence through strategic activities such as mergers and acquisitions, licensing, and partnerships.
Several noteworthy mergers and acquisitions have occurred in the market in recent years.
Some of the recent developments of key Cell and Gene Therapy Manufacturing providers are as follows:
Similarly, recent developments related to companies offering Cell and Gene Therapy Manufacturing have been tracked by the team at Future Market Insights, which are available in the full report.
The cell and gene therapy manufacturing market is expected to reach US$ 19.3 billion in 2023.
The market is anticipated to expand at a CAGR of 29%.
Constant developments and advancements in the cell and gene therapy manufacturing techniques are driving the market growth.
The United Kingdom market for cell and gene therapy manufacturing is forecast to expand at a CAGR of 23.9%.
The market leaders in the cell and gene therapy manufacturing market are Lonza, Catalent Inc., and Takara Bio Inc.
1. Executive Summary | Cell and Gene Therapy Manufacturing Marke 1.1. Global Market Outlook 1.2. Summary of Statistics 1.3. Key Market Characteristics & Attributes 1.4. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage 2.2. Market Definition 3. Market Risks and Trends Assessment 3.1. Risk Assessment 3.1.1. COVID-19 Crisis and Impact on Cell And Gene Therapy Manufacturing 3.1.2. COVID-19 Impact Benchmark with Previous Crisis 3.1.3. Impact on Market Value (US$ billion) 3.1.4. Assessment by Key Countries 3.1.5. Assessment by Key Market Segments 3.1.6. Action Points and Recommendation for Suppliers 3.2. Key Trends Impacting the Market 3.3. Formulation and Product Development Trends 4. Market Background 4.1. Cell And Gene Therapy Manufacturing Market, by Key Countries 4.2. Opportunity Assessment (US$ billion) 4.2.1. Total Available Market 4.2.2. Serviceable Addressable Market 4.2.3. Serviceable Obtainable Market 4.3. Market Scenario Forecast 4.3.1. Demand in optimistic Scenario 4.3.2. Demand in Likely Scenario 4.3.3. Demand in Conservative Scenario 4.4. Investment Feasibility Analysis 4.4.1. Investment in Established Markets 4.4.1.1. In Short Term 4.4.1.2. In Long Term 4.4.2. Investment in Emerging Markets 4.4.2.1. In Short Term 4.4.2.2. In Long Term 4.5. Forecast Factors - Relevance & Impact 4.5.1. Top Companies Historical Growth 4.5.2. Growth in Automation, By Country 4.5.3. Cell And Gene Therapy Manufacturing Adoption Rate, By Country 4.6. Market Dynamics 4.6.1. Market Driving Factors and Impact Assessment 4.6.2. Prominent Market Challenges and Impact Assessment 4.6.3. Opportunities 4.6.4. Prominent Trends in the Global Market & Their Impact Assessment 5. Key Success Factors 5.1. Manufacturers’ Focus on Low Penetration High Growth Markets 5.2. Banking on with Segments High Incremental Opportunity 5.3. Peer Benchmarking 6. Global Demand Analysis 2018 to 2022 and Forecast, 2023 to 2033 6.1. Historical Market Analysis, 2018 to 2022 6.2. Current and Future Market Projections, 2023 to 2033 6.3. Y-o-Y Growth Trend Analysis 7. Global Value Analysis 2018 to 2022 and Forecast, 2023 to 2033 7.1. Historical Market Value (US$ billion) Analysis, 2018 to 2022 7.2. Current and Future Market Value (US$ billion) Projections, 2023 to 2033 7.2.1. Y-o-Y Growth Trend Analysis 7.2.2. Absolute $ Opportunity Analysis 8. Global Analysis 2018 to 2022 and Forecast 2023 to 2033, By Therapy Type 8.1. Introduction / Key Findings 8.2. Historical Market Size (US$ billion) Analysis By Therapy Type, 2018 to 2022 8.3. Current and Future Market Size (US$ billion) Analysis and Forecast By Therapy Type, 2023 to 2033 8.3.1. Cell Therapy Manufacturing 8.3.1.1. Stem Cell Therapy 8.3.1.2. Non-Stem Cell Therapy 8.3.2. Gene Therapy Manufacturing 8.4. Market Attractiveness Analysis By Therapy Type 9. Global Analysis 2018 to 2022 and Forecast 2023 to 2033, By Scale 9.1. Introduction / Key Findings 9.2. Historical Market Size (US$ billion) Analysis By Scale, 2018 to 2022 9.3. Current and Future Market Size (US$ billion) Analysis and Forecast By Scale, 2023 to 2033 9.3.1. Pre-commercial/ R&D Scale Manufacturing 9.3.2. Gene Therapy Manufacturing 9.4. Market Attractiveness Analysis By Scale 10. Global Analysis 2018 to 2022 and Forecast 2023 to 2033, By Mode 10.1. Introduction / Key Findings 10.2. Historical Market Size (US$ billion) Analysis By Mode, 2018 to 2022 10.3. Current and Future Market Size (US$ billion) Analysis and Forecast By Mode, 2023 to 2033 10.3.1. Contract Manufacturing 10.3.2. In-house Manufacturing 10.4. Market Attractiveness Analysis By Mode 11. Global Analysis 2018 to 2022 and Forecast 2023 to 2033, By Workflow 11.1. Introduction / Key Findings 11.2. Historical Market Size (US$ billion) Analysis By Workflow, 2018 to 2022 11.3. Current and Future Market Size (US$ billion) Analysis and Forecast By Workflow, 2023 to 2033 11.3.1. Cell Processing 11.3.2. Cell Banking 11.3.3. Process Development 11.3.4. Fill & Finish Operations 11.3.5. Analytical And Quality Testing 11.3.6. Raw Material Testing 11.3.7. Vector Production 11.3.8. Other Workflows 11.4. Market Attractiveness Analysis By Workflow 12. Global Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 12.1. Introduction 12.2. Historical Market Size (US$ billion) Analysis By Region, 2018 to 2022 12.3. Current Market Size (US$ billion) & Analysis and Forecast By Region, 2023 to 2033 12.3.1. North America 12.3.2. Latin America 12.3.3. Europe 12.3.4. Asia Pacific 12.3.5. Middle East and Africa (MEA) 12.4. Market Attractiveness Analysis By Region 13. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033 13.1. Introduction 13.2. Pricing Analysis 13.3. Historical Market Value (US$ billion) Trend Analysis By Market Taxonomy, 2018 to 2022 13.4. Market Value (US$ billion) & Forecast By Market Taxonomy, 2023 to 2033 13.4.1. By Country 13.4.1.1. United States of America 13.4.1.2. Canada 13.4.1.3. Rest of North America 13.4.2. By Therapy Type 13.4.3. By Scale 13.4.4. By Workflow 13.4.5. By Mode 13.5. Market Attractiveness Analysis 13.5.1. By Country 13.5.2. By Therapy Type 13.5.3. By Scale 13.5.4. By Workflow 13.5.5. By Mode 14. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033 14.1. Introduction 14.2. Pricing Analysis 14.3. Historical Market Value (US$ billion) Trend Analysis By Market Taxonomy, 2018 to 2022 14.4. Market Value (US$ billion) & Forecast By Market Taxonomy, 2023 to 2033 14.4.1. By Country 14.4.1.1. Brazil 14.4.1.2. Mexico 14.4.1.3. Rest of Latin America 14.4.2. By Therapy Type 14.4.3. By Scale 14.4.4. By Workflow 14.4.5. By Mode 14.5. Market Attractiveness Analysis 14.5.1. By Country 14.5.2. By Therapy Type 14.5.3. By Scale 14.5.4. By Workflow 14.5.5. By Mode 15. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033 15.1. Introduction 15.2. Pricing Analysis 15.3. Historical Market Value (US$ billion) Trend Analysis By Market Taxonomy, 2018 to 2022 15.4. Market Value (US$ billion) & Forecast By Market Taxonomy, 2023 to 2033 15.4.1. By Country 15.4.1.1. Germany 15.4.1.2. France 15.4.1.3. United Kingdom 15.4.1.4. Italy 15.4.1.5. Benelux 15.4.1.6. Nordic Countries 15.4.1.7. Rest of Europe 15.4.2. By Therapy Type 15.4.3. By Scale 15.4.4. By Workflow 15.4.5. By Mode 15.5. Market Attractiveness Analysis 15.5.1. By Country 15.5.2. By Therapy Type 15.5.3. By Scale 15.5.4. By Workflow 15.5.5. By Mode 16. Asia Pacific Analysis 2018 to 2022 and Forecast 2023 to 2033 16.1. Introduction 16.2. Pricing Analysis 16.3. Historical Market Value (US$ billion) Trend Analysis By Market Taxonomy, 2018 to 2022 16.4. Market Value (US$ billion) & Forecast By Market Taxonomy, 2023 to 2033 16.4.1. By Country 16.4.1.1. China 16.4.1.2. Japan 16.4.1.3. South Korea 16.4.1.4. Rest of Asia Pacific 16.4.2. By Therapy Type 16.4.3. By Scale 16.4.4. By Workflow 16.4.5. By Mode 16.5. Market Attractiveness Analysis 16.5.1. By Country 16.5.2. By Therapy Type 16.5.3. By Scale 16.5.4. By Workflow 16.5.5. By Mode 17. Middle East and Africa Analysis 2018 to 2022 and Forecast 2023 to 2033 17.1. Introduction 17.2. Pricing Analysis 17.3. Historical Market Value (US$ billion) Trend Analysis By Market Taxonomy, 2018 to 2022 17.4. Market Value (US$ billion) & Forecast By Market Taxonomy, 2023 to 2033 17.4.1. By Country 17.4.1.1. GCC Countries 17.4.1.2. South Africa 17.4.1.3. Turkey 17.4.1.4. Rest of Middle East and Africa 17.4.2. By Therapy Type 17.4.3. By Scale 17.4.4. By Workflow 17.4.5. By Mode 17.5. Market Attractiveness Analysis 17.5.1. By Country 17.5.2. By Therapy Type 17.5.3. By Scale 17.5.4. By Workflow 17.5.5. By Mode 18. Key Countries Analysis 2018 to 2022 and Forecast 2023 to 2033 18.1. Introduction 18.1.1. Market Value Proportion Analysis, By Key Countries 18.1.2. Global Vs. Country Growth Comparison 18.2. US Analysis 18.2.1. Value Proportion Analysis by Market Taxonomy 18.2.2. Value Analysis and Forecast by Market Taxonomy, 2018-2033 18.2.2.1. By Therapy Type 18.2.2.2. By Scale 18.2.2.3. By Workflow 18.2.2.4. By Mode 18.3. Canada Analysis 18.3.1. Value Proportion Analysis by Market Taxonomy 18.3.2. Value Analysis and Forecast by Market Taxonomy, 2018-2033 18.3.2.1. By Therapy Type 18.3.2.2. By Scale 18.3.2.3. By Workflow 18.3.2.4. By Mode 18.4. Mexico Analysis 18.4.1. Value Proportion Analysis by Market Taxonomy 18.4.2. Value Analysis and Forecast by Market Taxonomy, 2018-2033 18.4.2.1. By Therapy Type 18.4.2.2. By Scale 18.4.2.3. By Workflow 18.4.2.4. By Mode 18.5. Brazil Analysis 18.5.1. Value Proportion Analysis by Market Taxonomy 18.5.2. Value Analysis and Forecast by Market Taxonomy, 2018-2033 18.5.2.1. By Therapy Type 18.5.2.2. By Scale 18.5.2.3. By Workflow 18.5.2.4. By Mode 18.6. Germany Analysis 18.6.1. Value Proportion Analysis by Market Taxonomy 18.6.2. Value Analysis and Forecast by Market Taxonomy, 2018-2033 18.6.2.1. By Therapy Type 18.6.2.2. By Scale 18.6.2.3. By Workflow 18.6.2.4. By Mode 18.7. France Analysis 18.7.1. Value Proportion Analysis by Market Taxonomy 18.7.2. Value Analysis and Forecast by Market Taxonomy, 2018-2033 18.7.2.1. By Therapy Type 18.7.2.2. By Scale 18.7.2.3. By Workflow 18.7.2.4. By Mode 18.8. Italy Analysis 18.8.1. Value Proportion Analysis by Market Taxonomy 18.8.2. Value Analysis and Forecast by Market Taxonomy, 2018-2033 18.8.2.1. By Therapy Type 18.8.2.2. By Scale 18.8.2.3. By Workflow 18.8.2.4. By Mode 18.9. BENELUX Analysis 18.9.1. Value Proportion Analysis by Market Taxonomy 18.9.2. Value Analysis and Forecast by Market Taxonomy, 2018-2033 18.9.2.1. By Therapy Type 18.9.2.2. By Scale 18.9.2.3. By Workflow 18.9.2.4. By Mode 18.10. UK Analysis 18.10.1. Value Proportion Analysis by Market Taxonomy 18.10.2. Value Analysis and Forecast by Market Taxonomy, 2018-2033 18.10.2.1. By Therapy Type 18.10.2.2. By Scale 18.10.2.3. By Workflow 18.10.2.4. By Mode 18.11. Nordic Countries Analysis 18.11.1. Value Proportion Analysis by Market Taxonomy 18.11.2. Value Analysis and Forecast by Market Taxonomy, 2018-2033 18.11.2.1. By Therapy Type 18.11.2.2. By Scale 18.11.2.3. By Workflow 18.11.2.4. By Mode 18.12. China Analysis 18.12.1. Value Proportion Analysis by Market Taxonomy 18.12.2. Value Analysis and Forecast by Market Taxonomy, 2018-2033 18.12.2.1. By Therapy Type 18.12.2.2. By Scale 18.12.2.3. By Workflow 18.12.2.4. By Mode 18.13. Japan Analysis 18.13.1. Value Proportion Analysis by Market Taxonomy 18.13.2. Value Analysis and Forecast by Market Taxonomy, 2018-2033 18.13.2.1. By Therapy Type 18.13.2.2. By Scale 18.13.2.3. By Workflow 18.13.2.4. By Mode 18.14. South Korea Analysis 18.14.1. Value Proportion Analysis by Market Taxonomy 18.14.2. Value Analysis and Forecast by Market Taxonomy, 2018-2033 18.14.2.1. By Therapy Type 18.14.2.2. By Scale 18.14.2.3. By Workflow 18.14.2.4. By Mode 18.15. GCC Countries Analysis 18.15.1. Value Proportion Analysis by Market Taxonomy 18.15.2. Value Analysis and Forecast by Market Taxonomy, 2018-2033 18.15.2.1. By Therapy Type 18.15.2.2. By Scale 18.15.2.3. By Workflow 18.15.2.4. By Mode 18.16. South Africa Analysis 18.16.1. Value Proportion Analysis by Market Taxonomy 18.16.2. Value Analysis and Forecast by Market Taxonomy, 2018-2033 18.16.2.1. By Therapy Type 18.16.2.2. By Scale 18.16.2.3. By Workflow 18.16.2.4. By Mode 18.17. Turkey Analysis 18.17.1. Value Proportion Analysis by Market Taxonomy 18.17.2. Value Analysis and Forecast by Market Taxonomy, 2018-2033 18.17.2.1. By Therapy Type 18.17.2.2. By Scale 18.17.2.3. By Workflow 18.17.2.4. By Mode 18.17.3. Competition Landscape and Player Concentration in the Country 19. Market Structure Analysis 19.1. Market Analysis by Tier of Companies 19.2. Market Concentration 19.3. Market Share Analysis of Top Players 19.4. Market Presence Analysis 19.4.1. By Regional footprint of Players 19.4.2. Product footprint by Players 20. Competition Analysis 20.1. Competition Dashboard 20.2. Competition Benchmarking 20.3. Competition Deep Dive 20.3.1. Thermo Fisher Scientific 20.3.1.1. Overview 20.3.1.2. Product Portfolio 20.3.1.3. Sales Footprint 20.3.1.4. Strategy Overview 20.3.2. Merck KGaA 20.3.2.1. Overview 20.3.2.2. Product Portfolio 20.3.2.3. Sales Footprint 20.3.2.4. Strategy Overview 20.3.3. Lonza 20.3.3.1. Overview 20.3.3.2. Product Portfolio 20.3.3.3. Sales Footprint 20.3.3.4. Strategy Overview 20.3.4. Catalent Inc. 20.3.4.1. Overview 20.3.4.2. Product Portfolio 20.3.4.3. Sales Footprint 20.3.4.4. Strategy Overview 20.3.5. Takara Bio Inc. 20.3.5.1. Overview 20.3.5.2. Product Portfolio 20.3.5.3. Sales Footprint 20.3.5.4. Strategy Overview 20.3.6. F. Hoffmann-La Roche Ltd 20.3.6.1. Overview 20.3.6.2. Product Portfolio 20.3.6.3. Sales Footprint 20.3.6.4. Strategy Overview 20.3.7. Wuxi Advanced Therapies 20.3.7.1. Overview 20.3.7.2. Product Portfolio 20.3.7.3. Sales Footprint 20.3.7.4. Strategy Overview 20.3.8. Samsung Biologics 20.3.8.1. Overview 20.3.8.2. Product Portfolio 20.3.8.3. Sales Footprint 20.3.8.4. Strategy Overview 20.3.9. Boehringer Ingelheim 20.3.9.1. Overview 20.3.9.2. Product Portfolio 20.3.9.3. Sales Footprint 20.3.9.4. Strategy Overview 20.3.10. Novartis AG 20.3.10.1. Overview 20.3.10.2. Product Portfolio 20.3.10.3. Sales Footprint 20.3.10.4. Strategy Overview 20.3.11. Hitachi Chemical Co., Ltd. 20.3.11.1. Overview 20.3.11.2. Product Portfolio 20.3.11.3. Sales Footprint 20.3.11.4. Strategy Overview 20.3.12. Cellular Therapeutics 20.3.12.1. Overview 20.3.12.2. Product Portfolio 20.3.12.3. Sales Footprint 20.3.12.4. Strategy Overview 20.3.12.5. Miltenyi Biotec Overview 20.3.12.6. Product Portfolio 20.3.12.7. Sales Footprint 20.3.12.8. Strategy Overview 20.3.13. Bluebird Bio Inc. 20.3.13.1. Overview 20.3.13.2. Product Portfolio 20.3.13.3. Sales Footprint 20.3.13.4. Strategy Overview 21. Assumptions and Acronyms Used 22. Research Methodology
Healthcare
April 2023
REP-GB-16106
303 pages
Explore Healthcare Insights
View Reports
Cell and Gene Therapy Manufacturing Market
